NSRX Stock Analysis: Buy, Sell, or Hold?
NSRX - Nasus Pharma Ltd.
$4.10
0.03 (0.74%)
▲
5d:
+12.33%
30d:
+32.69%
90d:
+44.88%
WAIT
LOW Confidence
Analysis Updated: Aug 25, 2026 12:00 AM ET
Earnings: Jun 24, 2026
0d
Get Alerted When NSRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NSRX is 10.2% above its trading range ($3.72). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NSRX is 10.2% above its trading range ($3.72). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: NSRX is currently trading at $4.10, which is considered extended relative to its 30-day fair value range of $3.03 to $3.72.
Technical Outlook: Technically, NSRX is in a uptrend. The price is approaching resistance at $4.10. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NSRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.67 (+379.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NSRX is in a uptrend. The price is approaching resistance at $4.10. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NSRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.67 (+379.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.03 -
$3.72
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+10.2% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 379.7% below Wall St target ($19.67)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.03 -
$3.72
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.05
Resistance Level
$4.10
Current Trend
Uptrend
Technical data as of
Aug 25, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.64
Wall Street Target
$19.67
(+379.7%)
Share & Embed Analysis
Last updated: August 25, 2026 8:54 PM ET
Data refreshes hourly during market hours. Next update: 9:54 PM
Data refreshes hourly during market hours. Next update: 9:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NSRX showing a specific setup today?
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1315 | 42 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 36 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 46 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$236 | 42 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 38 SELL |